Comparable effect of tolvaptan in heart failure patients with preserved or reduced ejection fraction

References

• Matsuzaki M, Hori M, Izumi T, Fukunami M, Investigators T. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study). Cardiovasc Drugs Ther. 2011;25(Suppl 1):S33–45. doi:10.1007/s10557-011-6304-x.
   PubMedGoogle Scholar
• Imamura T, Kinugawa K, Hatano M, Fujino T, Inaba T, Maki H, Kinoshita O, Nawata K, Kyo S, Ono M, et al. Low cardiac output stimulated vasopressin release in patients with stage d heart failure. Circ J. 2014;78:2259–67.
   PubMed Web of Science ®Google Scholar
• Matsukawa R, Kubota T, Okabe M, Yamamoto Y. Early use of V2 receptor antagonists is associated with shorter hospital stay and reduction in in-hospital death in patients with decompensated heart failure. Heart Vessels. 2016;31:1650–58. doi:10.1007/s00380-015-0780-z.
   PubMed Web of Science ®Google Scholar
• Kiuchi S, Hisatake S, Kabuki T, Oka T, Dobashi S, Fujii T, Ikeda T. The relationship between the time until commencement of tolvaptan and the length of hospital stay in heart failure patients. Heart Vessels. 2018;33:367–73. doi:10.1007/s00380-017-1067-3.
   PubMed Web of Science ®Google Scholar
• Tsutsui H, Isobe M, Ito H, JCS Joint Working Group (2017) Guidelines for diagnosis and treatment of acute and chronic heart failure (JCS 2017/JHFS 2017).
   Google Scholar
• McKee PA, Castelli WP, McNakamura PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Eng J Med. 1971;285:1441–46. doi:10.1056/NEJM197112232852601.
   PubMed Web of Science ®Google Scholar
• Mebazaa A, Gheorghiade M, Piña IL, Harjola VP, Hollenberg SM, Follath F, Rhodes A, Plaisance P, Roland E, Nieminen M, et al. Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes. Crit Care Med. 2008;36(Suppl 1):S129–39. doi:10.1097/01.CCM.0000296274.51933.4C.
   PubMedGoogle Scholar
• Kiuchi S, Hisatake S, Kabuki T, Oka T, Dobashi S, Fujii T, Ikeda T. Effect of switching from cilnidipine to azelnidipine on cardiac sympathetic nerve function in patients with heart failure preserved ejection fraction. Int Heart J. 2018;59:120–25. doi:10.1536/ihj.17-024.
   PubMed Web of Science ®Google Scholar
• Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92. doi:10.1053/j.ajkd.2008.12.034.
   PubMed Web of Science ®Google Scholar
• Schiller NB, Shah PN, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr. 1989;2:358–67.
   PubMed Web of Science ®Google Scholar
• Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–58. doi:10.1038/bmt.2012.244.
   PubMed Web of Science ®Google Scholar
• Hamaguchi S, Kinugawa S, Sobirin MA, Goto D, Tsuchihashi-Makaya M, Yamada S, Yokoshiki H, Tsutsui H, Investigators J-CARE-CARD. Mode of death in patients with heart failure and reduced vs. preserved ejection fraction: report from the registry of hospitalized heart failure patients. Circ J. 2012;(76):1662–69. doi:10.1253/circj.CJ-11-1355.
   PubMedGoogle Scholar
• Takada T, Sakata Y, Miyata S, Takahashi J, Nochioka K, Miura M, Tadaki S, Shimokawa H, CHART-2 Investigators. Impact of elevated heart rate on clinical outcomes in patients with heart failure with reduced and preserved ejection fraction: a report from the CHART-2 study. Eur J Heart Fail. 2014;16:309–16. doi:10.1002/ejhf.22.
   PubMed Web of Science ®Google Scholar
• McNamara DM, Starling RC, Cooper LT, Boehmer JP, Mather PJ, Janosko KM, Gorcsan J 3rd, Kip KE, Dec GW, IMAC Investigators. Clinical and demographic predictors of outcomes in recent onset dilated cardiomyopathy: results of the IMAC (Intervention in Myocarditis and Acute Cardiomyopathy)-2 study. J Am Coll Cardiol. 2011;58:1112–18. doi:10.1016/j.jacc.2011.05.033.
   PubMed Web of Science ®Google Scholar
• Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K, Billingham ME, Harrison DC, Stinson EB. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med. 1982;307:205–11. doi:10.1056/NEJM198207223070401.
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J, Zampino M, Orlandi C, Tolvaptan Investigators. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation. 2003;107:2690–96. doi:10.1161/01.CIR.0000070422.41439.04.
   PubMed Web of Science ®Google Scholar
• Oguri M, Ishii H, Ohguchi S, Takahara K, Kawamura Y, Yokoi Y, Izumi K, Takahashi H, Kamiya H, Murohara T. Comparison of two dosing methods for immediate administration of tolvaptan in acute decompensated heart failure. J Cardiol. 2018;72:234–39. doi:10.1016/j.jjcc.2018.02.006.
   PubMed Web of Science ®Google Scholar
• Tamaki S, Sato Y, Yamada T, Morita T, Furukawa Y, Iwasaki Y, Kawasaki M, Kikuchi A, Kondo T, Ozaki T, et al. Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure and preserved left ventricular ejection fraction- prospective randomized controlled study. Circ J. 2017;81:740–47. doi:10.1253/circj.CJ-16-1122.
   PubMed Web of Science ®Google Scholar
• Vaduganathan M, Gheorghiade M, Pang PS, Konstam MA, Zannad F, Swedberg K, Grinfeld L, Burnett JC Jr, Krasa HB, Zimmer C, et al. Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment. J Cardiovasc Med. 2012;13:415–22. doi:10.2459/JCM.0b013e328355a740.
   Google Scholar
• Kiuchi S, Ikeda T. Hemodynamic and hormonal effects of tolvaptan for heart failure. Intern Med. 2019;58:471–75. DOI: doi:10.2169/internalmedicine.1697-18.
   PubMed Web of Science ®Google Scholar
• Suzuki S, Yoshihisa A, Yamaki T, Sugimoto K, Kunii H, Nakazato K, Abe Y, Saito T, Ohwada T, Suzuki H, et al. Vasopressin V2 receptor antagonist tolvaptan is effective in heart failure patients with reduced left ventricular systolic function and low blood pressure. Int Heart J. 2015;56:213–18. doi:10.1536/ihj.14-248.
   PubMed Web of Science ®Google Scholar
• Payvar S, Spertus JA, Miller AB, Casscells SW, Pang PS, Zannad F, Swedberg K, Maggioni AP, Reid KJ, Gheorghiade M, et al. Association of low body temperature and poor outcomes in patients admitted with worsening heart failure: a substudy of the efficacy of vasopressin antagonism in heart failure outcome study with Tolvaptan (EVEREST) trial. Eur J Heart Fail. 2013;15:1382–89. doi:10.1093/eurjhf/hft113.
   PubMed Web of Science ®Google Scholar
• Atsumi W, Tani S, Tachibana E, Hirayama A. Combined evaluation of the plasma arginine vasopressin and noradrenaline levels may be a useful predictor of the prognosis of patients with acute decompensated heart failure. Int Heart J. 2018;59:791–801. doi:10.1536/ihj.17-244.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Funayama H, Yoshimura A, Tsuruya Y, Saito M, Kawakami M, Ishikawa SE. Possible vascular role of increased plasma arginine vasopressin in congestive heart failure. Int J Cardiol. 2006;106:191–95. doi:10.1016/j.ijcard.2005.01.043.
   PubMed Web of Science ®Google Scholar
• Eguchi A, Iwasaku T, Okuhara Y, Naito Y, Mano T, Masuyama T, Hirotani S. Long-term administration of tolvaptan increases myocardial remodeling and mortality via exacerbation of congestion in mice heart failure model after myocardial infarction. Int J Cardiol. 2016;221:302–09. doi:10.1016/j.ijcard.2016.07.034.
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Pang PS, Ambrosy AP, Lan G, Schmidt P, Filippatos G, Konstam M, Swedberg K, Cook T, Traver B, et al. A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial. Heart Fail Rev. 2012;17:485–509. doi:10.1007/s10741-011-9280-0.
   PubMed Web of Science ®Google Scholar
• Udelson JE, McGrew FA, Flores E, Ibrahim H, Katz S, Koshkarian G, O’Brien T, Kronenberg MW, Zimmer C, Orlandi C, et al. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J Am Coll Cardiol. 2007;49:2151–59. doi:10.1016/j.jacc.2007.01.091.
   PubMed Web of Science ®Google Scholar
• Hanatani A, Shibata A, Kitada R, Iwata S, Matsumura Y, Doi A, Sugioka K, Takagi M, Yoshiyama M. Administration of tolvaptan with reduction of loop diuretics ameliorates congestion with improving renal dysfunction in patients with congestive heart failure and renal dysfunction. Heart Vessels. 2017;32:287–94. doi:10.1007/s00380-016-0872-4.
   PubMed Web of Science ®Google Scholar
• Kiuchi S, Fujii T, Hisatake S, Oka T, Dobashi S, Fujii T, Ikeda T. Experience with long-term administration of tolvaptan to patients with acute decompensated heart failure. Drug Discov Ther. 2017;11:133–39. doi:10.5582/ddt.2017.01018.
   PubMed Web of Science ®Google Scholar
• Arimura T, Miura S, Morito N, Shiga Y, Kitajima K, Morii J, Iwata A, Fujimi K, Yahiro K, Sakua K. Recent patient characteristics and medications at admission and discharge in hospitalized patients with heart failure. J Clin Med Res. 2016;8:97–104. doi:10.14740/jocmr2402w.
   PubMedGoogle Scholar
• Konstam MA, Kiernan M, Chandler A, Dhingra R, Mody FV, Eisen H, Haught WH, Wagoner L, Gupta D, Patten R, et al. Short-term effects of Tolvaptan in patients with acute heart failure and volume overload. J Am Coll Cardiol. 2017;69:1409–19. doi:10.1016/j.jacc.2016.12.035.
   PubMed Web of Science ®Google Scholar
• Matsue Y, Suzuki M, Seya M, Iwatsuka R, Mizukami A, Nagahori W, Ohno M, Matsumura A, Hashimoto Y. Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure in high-risk population. J Cardiol. 2013;61:169–74. doi:10.1016/j.jjcc.2012.08.020.
   PubMed Web of Science ®Google Scholar
• Imamura T, Kinugawa K. Tolvaptan improves the long-term prognosis in patients with congestive heart failure with preserved ejection fraction as well as in those with reduced ejection fraction. Int Heart J. 2016;57:600–06. doi:10.1536/ihj.16-023.
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Ehara S, Nakamura Y, Otsuka K, Kawase Y. The effects of tolvaptan dose on cardiac mortality in patients with acute decompensated heart failure after hospital discharge. Heart Vessels. 2018;33:1204–13. doi:10.1007/s00380-018-1177-6.
   PubMed Web of Science ®Google Scholar
• Kono T, Tayama E, Hori H, Ueda T, Yamaki Y, Tanaka H. A safety and efficacy study of tolvaptan following open heart surgery in 109 cases. Int Heart J. 2016;57:496–502. doi:10.1536/ihj.15-483.
   PubMed Web of Science ®Google Scholar
• Imamura T, Kinugawa K, Komuro I. Tolvaptan prolongs blockage of the vasopressin type ii receptor over 24 hours in responders with Stage D heart failure. Int Heart J. 2016;57:41–46. doi:10.1536/ihj.15-297.
   PubMed Web of Science ®Google Scholar